Last reviewed · How we verify
Primary hypogonadism
Approved treatments
- Tlando · Tolmar
Tlando works by increasing testosterone levels in the body. - Aveed · Marius
Aveed works by binding to androgen receptors in the body, mimicking the effects of natural testosterone.
Clinical guidelines
- FDA label — 1L
Testosterone cypionate injection is indicated for replacement therapy in males with primary hypogonadism (congenital or acquired) due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, or orchidectomy. - FDA label — 1L
Testosterone cypionate injection is indicated for replacement therapy in males with hypogonadotropic hypogonadism (congenital or acquired) due to gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Primary hypogonadism patent landscape — cliff calendar, originator estates, attackable patents
- Primary hypogonadism treatment landscape brief
- Primary hypogonadism treatment updates RSS
Frequently asked questions about Primary hypogonadism
What drugs treat Primary hypogonadism?
Tracked treatments include Tlando, Aveed.
What is the treatment for Primary hypogonadism?
Standard treatment for Primary hypogonadism includes Tlando, Aveed. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Primary hypogonadism?
FDA label publishes guidelines for Primary hypogonadism. 2 guideline references tracked.
Related
- Treatment landscape: Primary hypogonadism patent cliff · Primary hypogonadism CI report
- Treatment: Tlando · Tolmar
- Treatment: Aveed · Marius
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing